BPC-157: What We Know—and What We Do Not

BPC-157 is the common name used for a synthetic 15-amino-acid peptide. FDA's 2026 review noted that published and marketed descriptions have used inconsistent names, which can make it difficult to know exactly which material a claim concerns. ^[3]

BPC-157 free base and BPC-157 acetate salt are different active pharmaceutical ingredients. Evidence about one form should not silently be transferred to the other, and a label that says only “BPC-157” may not resolve identity. ^{[3, 2]}

Descriptions sometimes call BPC-157 “gastric juice derived.” FDA's review explains that the peptide has reportedly been described as a fragment of a larger protein, but the exact parent protein has not been identified in humans. Origin language is therefore not clinical evidence or a safety credential. ^[3]

Interest is driven largely by claims involving musculoskeletal recovery, wound repair, inflammatory bowel disease, and tissue protection. FDA found that compounded BPC-157 products were promoted for uses including tendon and ligament injury, Crohn's disease, celiac disease, and other conditions. ^[3]

Cell and animal papers have proposed effects involving blood-vessel formation, nitric-oxide signaling, inflammation, and tissue response. These mechanisms are hypotheses about how an effect might occur; they do not establish that a patient will heal faster or experience better function. ^{[3, 8]}

The breadth of marketing claims is much larger than the human evidence base. A mechanistic story, animal injury model, or anecdote should not be translated into a claim that BPC-157 treats a named human disease or injury. ^{[3, 8]}

FDA staff identified five small, short human studies: a rectal-administration study in 24 healthy participants; an ulcerative-colitis study in approximately 26 people; a knee pain report in 17 people; an interstitial cystitis report in 12 people; and an intravenous study in two healthy participants. ^[3]

Context: Study counts do not make the studies confirmatory; design, reporting, comparator, duration, and data quality determine what can be concluded.

For the nominated ulcerative-colitis use, FDA found the clinical information inadequate to determine effectiveness. Reporting was incomplete, and the evidence did not provide the kind of controlled, reproducible outcomes needed to establish benefit. ^[3]

The knee-pain report was small and uncontrolled, and some participants reportedly received BPC-157 together with a thymosin-beta-4 product. That makes it impossible to isolate BPC-157's effect or draw a reliable conclusion about efficacy. ^{[3, 8]}

FDA identified no adequate human evidence for promoted tendon-healing uses or for Crohn's disease or celiac disease. The absence of adequate evidence is not evidence of benefit and should be stated plainly. ^[3]

FDA also identified a registered early-phase study that planned to enroll healthy participants, but no results were posted in the material reviewed. A registry entry shows that research was planned; it does not supply an outcome. ^[3]

A 2025 systematic review mapped an overwhelmingly preclinical literature, with studies concentrated in animal and laboratory models. It is useful for identifying hypotheses and gaps, not for converting those findings into proven human outcomes. ^[8]

Reported animal findings span different tissues, injury models, routes, preparations, endpoints, and study conditions. A positive signal in one model does not demonstrate that the same material reaches the relevant human tissue or improves pain, function, healing time, or disease activity. ^{[3, 8]}

Translation requires more than repeating an animal experiment: the substance must be characterized, exposure understood, clinically meaningful outcomes prespecified, and benefits and harms compared in adequately controlled human studies. ^{[3, 7]}

Serious adverse events did not appear to be reported in the small studies FDA reviewed. But the absence of reported serious adverse events is not proof of safety: the studies were short, enrolled few people, contained limited safety detail, and often did not clearly describe monitoring. ^[3]

FDA found no human pharmacokinetic information for several commonly promoted routes, including oral, subcutaneous, nasal, and transdermal use. Without exposure data, it is difficult to connect a preparation to either intended effects or toxicity. ^[3]

No formal immunogenicity studies were identified. As with other peptide products, aggregation and peptide-related impurities can influence immune risk; this is a reason for product-specific study, not proof that a particular reaction will occur. ^{[3, 6]}

Unapproved products add questions about identity, strength, purity, stability, sterility, and formulation. A laboratory paper cannot verify the quality of a product offered to a patient under the same peptide name. ^{[3, 4]}

The July 2026 review concerned whether BPC-157 free base and acetate salt should be included on the section 503A Bulks List for a nominated use in ulcerative colitis. It was not a new-drug-approval review. ^{[3, 2]}

FDA staff concluded that the available physical-chemical, safety, effectiveness, and historical-use information weighed against placing both forms on the 503A Bulks List. That conclusion reflects the statutory compounding criteria and the evidence FDA reviewed. ^[3]

The Pharmacy Compounding Advisory Committee provides advice to FDA; its recommendations are not binding. A committee discussion is not FDA approval, and a recommendation against list placement is not the same thing as declaring that the molecule is banned in every context. ^{[5, 1, 2]}

FDA's current compounding-risk page lists BPC-157 among substances that may present significant safety risks and highlights limited safety information and immunogenicity or impurity concerns. That page is a risk signal, not a complete incidence estimate or a substitute for product-specific clinical data. ^[4]

Which exact substance is being discussed—free base or acetate salt—and what evidence verifies identity, purity, strength, stability, and sterility for the specific product? ^{[3, 6]}

Is the claimed benefit supported by a controlled human study of that substance and route, measuring a patient-important outcome, or is the claim being inferred from cells, animals, anecdotes, or a different material? ^{[3, 8]}

What remains unknown about human exposure, interactions, immune reactions, reproductive or developmental effects, longer-term toxicity, and adverse-event detection—and is that uncertainty being presented as clearly as the proposed benefit? ^{[3, 7, 6]}